HC Wainwright Reaffirms “Buy” Rating for TScan Therapeutics (NASDAQ:TCRX)

TScan Therapeutics (NASDAQ:TCRX)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a report issued on Tuesday, Benzinga reports. They presently have a $15.00 target price on the stock. HC Wainwright’s price target would indicate a potential upside of 150.00% from the company’s current price.

TCRX has been the subject of several other research reports. Wedbush reaffirmed an “outperform” rating and set a $10.00 price target on shares of TScan Therapeutics in a research report on Monday. BTIG Research assumed coverage on TScan Therapeutics in a research report on Thursday, May 16th. They issued a “buy” rating and a $12.00 target price on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $11.00 target price on shares of TScan Therapeutics in a report on Monday. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $12.00.

TScan Therapeutics Stock Up 1.4 %

Shares of NASDAQ TCRX opened at $6.00 on Tuesday. The firm has a market cap of $317.16 million, a P/E ratio of -4.69 and a beta of 0.83. The company has a debt-to-equity ratio of 0.19, a quick ratio of 5.23 and a current ratio of 5.23. TScan Therapeutics has a 1 year low of $1.97 and a 1 year high of $9.69. The firm’s 50 day moving average price is $6.93 and its 200 day moving average price is $7.16.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings results on Monday, May 13th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.07). TScan Therapeutics had a negative net margin of 653.50% and a negative return on equity of 61.13%. The business had revenue of $0.57 million during the quarter, compared to analysts’ expectations of $3.75 million. As a group, sell-side analysts anticipate that TScan Therapeutics will post -1.25 earnings per share for the current year.

Institutional Trading of TScan Therapeutics

A number of institutional investors have recently added to or reduced their stakes in TCRX. Tocqueville Asset Management L.P. purchased a new stake in shares of TScan Therapeutics in the first quarter worth about $1,685,000. abrdn plc purchased a new position in TScan Therapeutics in the 4th quarter valued at about $1,166,000. Bank of New York Mellon Corp acquired a new stake in TScan Therapeutics during the 2nd quarter valued at approximately $682,000. Brown Brothers Harriman & Co. bought a new position in TScan Therapeutics during the 2nd quarter valued at $445,000. Finally, Rhumbline Advisers acquired a new position in TScan Therapeutics in the second quarter worth about $274,000. 82.83% of the stock is owned by hedge funds and other institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.